Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase 1 study
Publication date
2008Author
Albertella, M.R.Loadman, Paul
Jones, P.H.
Phillips, Roger M.
Rampling, R.
Burnet, N.
Alcock, C.
Anthoney, Alan
Vjaters, E.
Dunk, C.R.
Harris, P.A.
Wong, A.
Lalani, A.S.
Twelves, Christopher J.
Keyword
REF 2014; Hypoxia; Bioreductive prodrug; Topoisomerase II inhibitor; Pharmacodynamics; Tumor-targeting;AQ4N
Peer-Reviewed
yes